Free Trial
TSE:EDT

Spectral Medical Q2 2024 Earnings Report

Spectral Medical logo
C$0.86 -0.01 (-1.15%)
As of 01:48 PM Eastern

Spectral Medical EPS Results

Actual EPS
-C$0.02
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Spectral Medical Revenue Results

Actual Revenue
$0.47 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Spectral Medical Announcement Details

Quarter
Q2 2024
Time
N/A
Conference Call Date
Friday, August 9, 2024
Conference Call Time
2:15AM ET

Earnings Documents

Spectral Medical Earnings Headlines

Trump Quietly Planning $15 Trillion Crypto Shocker
Most investors are still unaware, but I believe a new White House action may have quietly opened the floodgates for a $15 trillion crypto surge. My latest crypto playbook reveals the coin I’m most bullish on—including the name, ticker, and why I’m investing personal capital into it.
Stocks in play: Spectral Medical Inc.
Spectral Medical Advances Amid Tigris Trial Challenges
See More Spectral Medical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Spectral Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Spectral Medical and other key companies, straight to your email.

About Spectral Medical

Spectral Medical (TSE:EDT) Inc is focused on the development and commercialization of a treatment for septic shock utilizing its endotoxin activity assay (EAA) diagnostic and the toraymyxin therapeutic. The company also manufactures and sells proprietary reagents. The product line of the company consists of proprietary biochemical, EAA, and instrumentation. The segments of the group are Spectral Medical Inc, which is the key revenue-generating segment that manufactures and sells its EAA diagnostic and certain proprietary reagents; Dialco Medical Inc segment; and Corporate.

View Spectral Medical Profile

More Earnings Resources from MarketBeat